{"preliminary_commentary":{"by_channel":{"x_thread":334,"youtube":175,"podcast":121,"bluesky_thread":25,"x_video":13},"note":"Preliminary. Indexed podcasts, YouTube videos and X posts that name this trial so far. This is where a report starts, not where it ends: the build searches for more, so finished reports usually cover more than this."},"free_build":{"available":true,"how":"POST https://www.erudio.com/api/trial-requests with {\"nct_id\": \"NCT04592913\", \"email\": \"<work email>\"}. The person who owns that inbox must confirm by the emailed link; agents cannot confirm. The result is the report's free public preview; the full report is still bought."},"commentary_summary":null,"name":"MATTERHORN","nct_id":"NCT04592913","offer":{"currency":"USD","how":"Order at https://www.erudio.com/contact?report=matterhorn-nct04592913. The price is an estimate of verified statements from the commentary indexed so far, fixed at order. Final coverage is set when the report is built. We build the report within 24 hours of confirming the order and deliver it when it passes our checks; if it cannot be built to our standard, nothing is charged.","price_usd":1950,"size":"deep","size_rule":"Deep: 301+ verified statements, estimated at 14 per indexed commentary source"},"registry":{"acronym":null,"arms":[{"description":"placebo product and FLOT chemotherapy","label":"Arm B","type":"PLACEBO_COMPARATOR"},{"description":"Durvalumab and FLOT chemotherapy","label":"Arm A","type":"EXPERIMENTAL"}],"collaborators":[],"completion_date":{"date":"2027-09-27","type":"ESTIMATED"},"conditions":["Gastrointestinal Neoplasms","Esophagogastric Junction"],"enrollment":{"count":957,"type":"ACTUAL"},"has_results":false,"interventions":[{"name":"Durvalumab","otherNames":[],"type":"DRUG"},{"name":"FLOT chemotherapy","otherNames":[],"type":"DRUG"}],"last_update":"2025-12-24","lead_sponsor":"AstraZeneca","official_title":"A Randomized, Double-blind, Placebo-controlled, Phase III Study of Neoadjuvant-Adjuvant Durvalumab and FLOT Chemotherapy Followed by Adjuvant Durvalumab in Patients With Resectable Gastric and Gastroesophageal Junction Cancer (GC/GEJC)","overall_status":"ACTIVE_NOT_RECRUITING","phases":["PHASE3"],"primary_completion_date":{"date":"2024-12-20","type":"ACTUAL"},"primary_outcomes":[{"measure":"Event-free survival (EFS)","timeFrame":"Up to 5 years"}],"references":[{"citation":"Janjigian YY, Al-Batran SE, Wainberg ZA, Muro K, Molena D, Van Cutsem E, Hyung WJ, Wyrwicz L, Oh DY, Omori T, Moehler M, Bragagnoli AC, Garbaos G, Liberman M, Miron MLL, Smyth EC, Cheng LY, Robbins SH, Valeri N, Xynos I, Tabernero J; MATTERHORN investigators. Perioperative durvalumab plus fluorouracil, leucovorin, oxaliplatin, and docetaxel for resectable gastric and gastro-oesophageal junction adenocarcinoma (MATTERHORN): final results of overall survival and event-free survival by pathological response in a global, randomised, double-blind, placebo-controlled, multicentre, phase 3 trial. Lancet. 2026 Sep 9:S0140-6736(26)01254-7. doi: 10.1016/S0140-6736(26)01254-7. Online ahead of print.","pmid":"42716074","type":"DERIVED"},{"citation":"Janjigian YY, Al-Batran SE, Wainberg ZA, Muro K, Molena D, Van Cutsem E, Hyung WJ, Wyrwicz L, Oh DY, Omori T, Moehler M, Garrido M, Oliveira SCS, Liberman M, Oliden VC, Smyth EC, Stein A, Bilici M, Alvarenga ML, Kozlov V, Rivera F, Kawazoe A, Serrano O, Heilbron E, Negro A, Kurland JF, Tabernero J; MATTERHORN Investigators. Perioperative Durvalumab in Gastric and Gastroesophageal Junction Cancer. N Engl J Med. 2025 Jul 17;393(3):217-230. doi: 10.1056/NEJMoa2503701. Epub 2025 Jun 1.","pmid":"40454643","type":"DERIVED"},{"citation":"Chang X, Ge X, Zhang Y, Xue X. The current management and biomarkers of immunotherapy in advanced gastric cancer. Medicine (Baltimore). 2022 May 27;101(21):e29304. doi: 10.1097/MD.0000000000029304.","pmid":"35623069","type":"DERIVED"},{"citation":"Janjigian YY, Van Cutsem E, Muro K, Wainberg Z, Al-Batran SE, Hyung WJ, Molena D, Marcovitz M, Ruscica D, Robbins SH, Negro A, Tabernero J. MATTERHORN: phase III study of durvalumab plus FLOT chemotherapy in resectable gastric/gastroesophageal junction cancer. Future Oncol. 2022 Jun;18(20):2465-2473. doi: 10.2217/fon-2022-0093. Epub 2022 May 10.","pmid":"35535555","type":"DERIVED"},{"citation":"Cowzer D, Janjigian YY. Top advances in esophageal/gastroesophageal junction cancers in 2021. Cancer. 2022 May 15;128(10):1894-1899. doi: 10.1002/cncr.34140. Epub 2022 Feb 18. No abstract available.","pmid":"35179774","type":"DERIVED"}],"start_date":{"date":"2020-11-17","type":"ACTUAL"},"study_type":"INTERVENTIONAL","title":"Assessing Durvalumab and FLOT Chemotherapy in Resectable Gastric and Gastroesophageal Junction Cancer","url":"https://clinicaltrials.gov/study/NCT04592913"},"report":null,"schema_id":"erudio.trial_listing","schema_version":"3.0","state":"listed","state_text":"No report yet. It can be ordered.","url":"https://www.erudio.com/trials/matterhorn-nct04592913"}